After failing primary and secondary hormonal therapy, castration-resistant and neuroendocrine prostate cancer metastatic to the bone is invariably lethal, although treatment with docetaxel and ...

Savita Dandapani, MD, PhD, discusses the rationale behind a study evaluating the combination of radium-223, hormone therapy, and SBRT in metastatic castration-sensitive prostate cancer.

There are currently, however, two radioligands that are United States Food and Drug Administration (FDA)-approved for the treatment of mCRPC patients: Patients with advanced prostate cancer are at ...

Copyright held by the owner/author(s).

Lymph nodes near the prostate are also often affected. Prostate cancer has a tendency to spread to the bones, specifically the pelvis, upper legs, and lower spine. While those are the most common ...

Radiotherapy and surgery are curative treatment options for localized prostate cancer (PCa) with a 5-year survival rate of nearly 100%. Once PCa cells spread into distant organs, such as bone, the ...

A new UCSF study shows a significant increase in advanced prostate cancer cases in California, growing faster than the ...

Intravenous; mCRPC: Metastatic castration-resistant prostate cancer; P: Placebo ... the incidence of skeletal-related events (SREs) in bone metastatic CRPC (mCRPC). Denosumab compared with ...

Explore the role of the extracellular matrix (ECM) in prostate cancer progression and discover natural therapies, including ...

Further tests, such as CT scans and bone scans, may be performed to determine whether prostate cancer has spread. Management strategies for prostate cancer should be guided the severity of the ...

[25] The preferential metastatic sites in 316 patients with PC were bone (89.5% ... BM: Brain metastasis; CRPC: Castration-resistant prostate cancer; CT: Computed tomography; NA: Not assessed ...